Core Viewpoint - The company and its subsidiary have received approval from the National Medical Products Administration for two drug clinical trial notifications, which will commence shortly [1] Drug Details - **Injection SHR-9839 (sc)** - Indication: Advanced colorectal cancer - Mechanism: Humanized antibody that simultaneously blocks two key tumor signaling pathways - Progress: Initiating Phase Ib/II clinical study in combination with anti-tumor therapy - Competitive Landscape: One drug targeting the same pathway has been approved globally - Cumulative R&D Investment: Approximately 93.9 million [1] - **HRS-4642 Injection** - Indication: KRAS G12D mutation tumors - Mechanism: KRAS G12D inhibitor (liposome formulation) - Competitive Landscape: No similar drugs have been approved for marketing domestically or internationally - Cumulative R&D Investment: Approximately 254.2 million [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Cutia Therapeutics 科笛集團 （於開曼群島註冊成立之有限公司） （股份代號：2487） 1 CU-20101在生產工藝過程中將不使用動物源性材料，從而消除傳染性海綿狀腦病 (TSE)感染和相關過敏反應風險，預計將具有良好的安全性優勢。CU-20101將進 一步豐富本集團的皮膚產品矩陣，並有利於與本集團現有產品形成協同效應。面 向皮膚治療市場廣泛的需求，多元化產品的佈局將有望為本集團取得更大的市場 份額。 自願公告 CU-20101（注射用A型肉毒毒素）用於改善中度至重度眉間紋的 中國III期臨床試驗取得積極的頂線結果 本公告由科笛集團（「本公司」，連同其附屬公司統稱「本集團」）自願刊發，以告知 本公司股東及潛在投資者有關本集團最新業務發展資料。 本公司董事會（「董事會」）欣然宣佈，本集團CU-20101（注射用A型肉毒毒素）用 於改善中度至重度眉間紋的中國III期臨床試驗（「該臨床試驗 ...

Group 1 - The company, China Resources Double Crane (华润双鹤), announced that its wholly-owned subsidiary, Beijing Double Crane Run Chuang Technology Co., Ltd., has received an implied approval from the FDA for the clinical trial application of the drug DC6001, marking the drug's advancement to the clinical trial phase [1] - The drug is indicated for Stargardt disease, with an IND number of 178781, and the total R&D investment amounts to 17.36 million yuan (approximately 2.5 million USD) [1] - The IND application was submitted to the FDA on November 26, 2025, and the confirmation letter was received on December 9, 2025, indicating that the implied approval period has expired, and the company will proceed with subsequent clinical trial work as required by the FDA [1] Group 2 - Additionally, the subsidiary applied for orphan drug designation for a rare pediatric disease on September 23, 2025, which was approved on November 24, 2025; however, there is uncertainty regarding policy support, and final market approval cannot be guaranteed [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Beijing Shuanghe Run Chuang Technology Co., Ltd., has received implied permission from the FDA for clinical trials of the drug DC6001, marking a significant step in its development process [1][2]. Group 1: Drug Information - Drug Name: DC6001 - Dosage Form: Tablet - IND Number: 178781 - Applicant: Beijing Shuanghe Run Chuang Technology Co., Ltd. - Indication: Stargardt disease [6]. Group 2: Regulatory Milestones - The IND application for DC6001 was submitted to the FDA on November 26, 2025, and the confirmation letter was received on December 9, 2025. The implied permission period has now expired, allowing the company to proceed with clinical trials [2]. - The drug received Rare Pediatric Disease Designation (RPDD) from the FDA on November 24, 2025, which may provide certain policy support in the future, although this is subject to regulatory changes [2]. Group 3: Financial Investment - As of the announcement date, the total R&D investment for the drug DC6001 amounts to approximately RMB 17.36 million (unaudited) [3].

Core Viewpoint - China Resources Double Crane (600062.SH) announced that its wholly-owned subsidiary, Beijing Double Crane Run Chuang Technology Co., Ltd. (referred to as "Double Crane Run Chuang"), has received effective approval from the FDA for the new drug clinical trial application (IND) for DC6001 tablets, marking the drug's entry into the clinical trial phase [1] Group 1 - The drug DC6001 is currently in the early stages of clinical development, pending confirmation of safety, efficacy, and quality control through clinical trials [1] - The drug is subject to objective failure rates and other associated risks during the clinical trial process [1] - According to U.S. drug registration laws and regulations, a series of clinical studies must be conducted in the U.S. and approved by the FDA before the drug can be marketed [1]

Core Viewpoint - The successful GCP registration of Zoucheng People's Hospital marks a significant milestone, enabling the hospital to conduct drug clinical trials, which will enhance clinical research, new drug development, and patient treatment opportunities in the Zoucheng area [1][5]. Group 1: GCP Registration and Its Implications - Zoucheng People's Hospital has officially obtained the qualification to conduct drug clinical trials through the GCP registration [1]. - This achievement is expected to drive the hospital's transformation from "clinical medicine" to a dual focus on "medical care + research," enhancing its research capabilities and professional standards [5]. Group 2: Inspection and Feedback Process - In September of the previous year, the Shandong Provincial Food and Drug Review and Inspection Center conducted an initial inspection of the hospital's drug clinical trial institution, evaluating various aspects such as organizational structure, personnel training, and quality management [3]. - The inspection included a thorough review of facilities and compliance with GCP regulations, with experts providing guidance and feedback to improve the institution's operations [3]. Group 3: Future Development Plans - Following the feedback from the inspection, the hospital's leadership has committed to addressing identified issues and enhancing the quality management systems and standard operating procedures for clinical trials [5]. - The hospital plans to expand the scope of its drug clinical trials and ensure compliance with national laws and regulations, aiming for high-quality development in medical research [5].

Group 1 - The clinical trial for Sichuan Huiyu Pharmaceutical Co., Ltd.'s Isomaltosyl Iron Injection has been initiated, focusing on its bioequivalence in participants with iron deficiency anemia [1] - The trial is registered under CTR20260095, with the first public information date set for January 9, 2026 [1] - The primary objective is to compare the absorption levels and rates of the company's Isomaltosyl Iron Injection with that of Pharmacosmos A/S in a fasting state [1] Group 2 - The trial is currently ongoing and has not yet recruited participants, with a target enrollment of 24 individuals [2] - The drug is indicated for iron deficiency anemia, which is characterized by symptoms such as fatigue and dizziness due to insufficient iron intake or absorption [1] - Key endpoints of the trial include Cmax, AUC0-t, and AUC0-∞, with secondary endpoints including Tmax, λz, t1/2, and AUC_%Extrap [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for four drug clinical trials, focusing on prostate cancer-related multi-center, open-label Phase II clinical research [1] Drug Approval Summary - **SHR-4394 Injection**: - Indication: Prostate cancer - Cumulative R&D investment: 38.4 million yuan - No similar products approved domestically or internationally [1] - **HRS-5041 Tablets**: - A novel AR PROTAC small molecule for prostate cancer - Cumulative R&D investment: 92.66 million yuan - Potential to overcome drug resistance; no similar products available [1] - **Zemiglozole Tablets**: - EZH2 inhibitor, approved for market in 2025 - Cumulative R&D investment: 216.82 million yuan - Similar products expected to generate approximately 51 million USD in global sales by 2024 [1] - **Rivolumab Tablets**: - Second-generation AR inhibitor, approved in 2022 - Cumulative R&D investment: 696.72 million yuan - Similar products projected to achieve around 11.037 billion USD in global sales by 2024 [1]

Core Insights - The Suzhou Northern People's Hospital Clinical Pharmacology Research Center successfully passed the professional filing inspection for its bioequivalence testing specialty, marking a significant advancement in the hospital's clinical trial capabilities and contributing to the high-quality development of regional drug clinical trials [1][2]. Group 1: Inspection and Achievements - The Clinical Pharmacology Research Center underwent its first on-site inspection by experts from the Jiangsu Provincial Drug Supervision Administration on November 11-12, 2025, demonstrating thorough preparation by the research team led by Professor Shu Yusheng [1]. - The center currently has 28 drug clinical trial specialties and 41 medical device clinical trial specialties, capable of undertaking various clinical trial projects [1]. Group 2: Future Plans and Development - Following the successful filing of the bioequivalence testing specialty, the center aims to enhance its clinical trial quality management system and promote standardized processes, thereby elevating the hospital's research and clinical trial standards [2]. - Since its establishment in December 2023, the center has adhered to national regulations and quality management standards, with a facility covering approximately 3,600 square meters, equipped with 72 beds and 2 emergency beds [2]. - The center's research team consists of 16 staff members, including 10 with senior titles and 2 with intermediate titles, and features members from national and provincial drug clinical trial expert databases [2]. Group 3: Next Steps - The center plans to actively advance the filing application for its Phase I drug clinical trial specialty, aiming to undertake more high-quality innovative drug Phase I clinical trial projects [3].

Core Viewpoint - Aclaris Therapeutics has announced positive interim results from its ATI-052 Phase Ia clinical trial, which involved both single and multiple ascending doses [1]. Group 1: Clinical Trial Results - The conference call was held to review the interim results of the ATI-052 trial, indicating a significant step forward for the company [1]. - The press release detailing these clinical results was made available on the company's Investor Relations website [1]. Group 2: Communication and Presentation - The conference included a presentation with slides that are accessible as a downloadable PDF document during the webcast [2]. - A Q&A session was scheduled to follow the prepared remarks, allowing for further discussion on the trial results [2].